Theranostics in Practice: Lessons Learned from Clinical Perspectives-Part 1.
Saved in:
| Title: | Theranostics in Practice: Lessons Learned from Clinical Perspectives-Part 1. |
|---|---|
| Authors: | Anleu F; BAMF Health, Grand Rapids, Michigan; and fernando.anleu@bamfhealth.com., Beyder D; Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri. |
| Source: | Journal of nuclear medicine technology [J Nucl Med Technol] 2025 Dec 04; Vol. 53 (Suppl 1), pp. 74S-81S. Date of Electronic Publication: 2025 Dec 04. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0430303 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5675 (Electronic) Linking ISSN: 00914916 NLM ISO Abbreviation: J Nucl Med Technol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Reston, VA : Society of Nuclear Medicine Original Publication: New York. |
| MeSH Terms: | Theranostic Nanomedicine*/methods , Precision Medicine*/methods, Humans ; Nuclear Medicine |
| Abstract: | Theranostics is changing how we approach treatment in nuclear medicine. Combining targeted imaging with radiopharmaceutical therapy allows us to personalize care in ways that were not previously possible. As this field grows, so does the need for strong coordination, clear protocols, and effective teamwork. From the technologist's perspective, these treatments are rewarding but also complex, requiring attention to detail and flexibility in clinical care. This article shares lessons learned from working directly with patients and teams involved in delivering theranostics care. It covers practical takeaways in patient selection, imaging setup, scan preparation, and therapy workflows, with specific examples from thyroid cancer, neuroendocrine tumors, and prostate cancer. We also reflect on how communication, posttherapy follow-up, and technologist-led problem-solving can significantly impact patient outcomes and satisfaction. Through every phase, we highlight the importance of collaboration, clarity, and preparation in making these therapies successful. We share these lessons as a reflection of what we have learned thus far in this evolving field. Every step has taught us something new about the care we provide, the teams with whom we work, and the impact we can have. As technologists, we are proud to be part of this next chapter in nuclear medicine. (© 2025 by the Society of Nuclear Medicine and Molecular Imaging.) |
| Contributed Indexing: | Keywords: dosimetry; nuclear medicine technologist; patient selection; radiopharmaceutical therapy; theranostics |
| Entry Date(s): | Date Created: 20251204 Date Completed: 20251204 Latest Revision: 20251204 |
| Update Code: | 20251205 |
| DOI: | 10.2967/jnmt.125.271202 |
| PMID: | 41344835 |
| Database: | MEDLINE |
Nájsť tento článok vo Web of Science | Abstract: | Theranostics is changing how we approach treatment in nuclear medicine. Combining targeted imaging with radiopharmaceutical therapy allows us to personalize care in ways that were not previously possible. As this field grows, so does the need for strong coordination, clear protocols, and effective teamwork. From the technologist's perspective, these treatments are rewarding but also complex, requiring attention to detail and flexibility in clinical care. This article shares lessons learned from working directly with patients and teams involved in delivering theranostics care. It covers practical takeaways in patient selection, imaging setup, scan preparation, and therapy workflows, with specific examples from thyroid cancer, neuroendocrine tumors, and prostate cancer. We also reflect on how communication, posttherapy follow-up, and technologist-led problem-solving can significantly impact patient outcomes and satisfaction. Through every phase, we highlight the importance of collaboration, clarity, and preparation in making these therapies successful. We share these lessons as a reflection of what we have learned thus far in this evolving field. Every step has taught us something new about the care we provide, the teams with whom we work, and the impact we can have. As technologists, we are proud to be part of this next chapter in nuclear medicine.<br /> (© 2025 by the Society of Nuclear Medicine and Molecular Imaging.) |
|---|---|
| ISSN: | 1535-5675 |
| DOI: | 10.2967/jnmt.125.271202 |